Retrieved from Novo Nordisk-f
A pooled analysis of the STEP 1-3 trials (n=2,117 semaglutide 2.4 mg, n=1,262 placebo) reported GI adverse events in 72.9% of the semaglutide group versus 47.1% of placebo, with nausea (43.9% vs 16.1%), diarrhea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%), and constipation (24.2% vs 11.1%) the most common categories
People who want help avoiding counterfeit or illegally marketed research products sold for self-use
Studies have shown that NSAID use in patients with altered gastrointestinal motility correlates with higher rates of upper GI adverse events
It gets even better its rich in leucine, a key trigger for muscle protein synthesis
Loffredo, L., Pignatelli, P., Cangemi, R., Andreozzi, P., Panico, M